80 results found.

Myelodysplastic Syndrome Clinical Trial using Antibiotic and antifungal drugs

Gruppo Italiano Malattie EMatologiche dell'Adulto - Recruiting 18 years or older.
- Observational Prospective Multicenter Study to Evaluate the Infective Risk in Myelodysplastic Syndrome Patients: Antimicrobial Prophylaxis and Granulocyte Growth Factors..
Antibiotic and antifungal drugs

Myelodysplastic Syndromes, or Leukemia, Myelomonocytic, Chronic Clinical Trial using Azacitidine; Volasertib

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label Phase I Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics and Efficacy of Intravenous Volasertib in Combination With Subcutaneous Azacitidine in Patients With Previously Untreated High-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Ineligible for High-intensity Therapy.
Azacitidine; Volasertib

Disorder Related to Bone Marrow Transplantation, Leukemia, or Tra Clinical Trial using Fludarabine; Clofarabine; Busulfan; Thymoglobulin; Stem Cell Infusion; Tacrolimus; Methotrexate

M.D. Anderson Cancer Center - Recruiting 3 years to 70 years.
- A Randomized Study of Once Daily Fludarabine-Clofarabine Versus Fludarabine Alone Combined With Intervenous Busulfan Followed by Allogeneic Hemopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).
Fludarabine; Clofarabine; Busulfan; Thymoglobulin; Stem Cell Infusion; Tacrolimus; Methotrexate

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, or Myelodys Clinical Trial using Allopurinol; Keppra; Busulfan; Cyclophosphamide; Cyclosporine A; Mycophenolate mofetil; Allogeneic hematopoietic stem cell transplant; Filgrastim; antithymocyte globulin

Masonic Cancer Center, University of Minnesota - Recruiting N/A to 44 years.
- Busulfan and Cyclophosphamide Followed By Allogeneic Hematopoietic Cell Transplantation In Patients With Hematological Malignancies.
Allopurinol; Keppra; Busulfan; Cyclophosphamide; Cyclosporine A; Mycophenolate mofetil; Allogeneic hematopoietic stem cell transplant; Filgrastim; antithymocyte globulin

Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Myeloid Leukemia, Mul Clinical Trial using Dasatinib; laboratory biomarker analysis

Barbara Ann Karmanos Cancer Institute - Recruiting 18 years or older.
- Phase I/II Study of Dasatinib in Recipients of Allogeneic Stem Cell Transplantation for Hematologic Malignancies..
Dasatinib; laboratory biomarker analysis

MonoMAC, Myelodysplastic Syndrome, or Immunodeficiency Clinical Trial using Reduced-Intensity Hematopoietic Stem Cell; Fludarabine; Total Body Irradiation (TBI); Filgrastim; Sirolimus; Tacrolimus; Ursodiol

National Institutes of Health Clinical Center (CC) - Recruiting 12 years to 60 years.
- Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for Patients With GATA2 Mutations.
Reduced-Intensity Hematopoietic Stem Cell; Fludarabine; Total Body Irradiation (TBI); Filgrastim; Sirolimus; Tacrolimus; Ursodiol

Leukemia Clinical Trial using Eltrombopag; Hypomethylating Agent (HMA)

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Phase II Study of Eltrombopag With or Without Continuation of Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS).
Eltrombopag; Hypomethylating Agent (HMA)

Leukemia Clinical Trial using Vosaroxin; Decitabine

M.D. Anderson Cancer Center - Recruiting 60 years or older.
- A Phase I/II Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome.
Vosaroxin; Decitabine

Leukemia Clinical Trial using Ruxolitinib

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Phase I Study of Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS).
Ruxolitinib

Leukemia Clinical Trial using Clofarabine; Idarubicin; Cytarabine; Fludarabine

M.D. Anderson Cancer Center - Recruiting 18 years to 60 years.
- Phase I/II Randomized Study of Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome.
Clofarabine; Idarubicin; Cytarabine; Fludarabine

Leukemia Clinical Trial using Cladribine; Cytarabine; Decitabine

M.D. Anderson Cancer Center - Recruiting 60 years or older.
- Phase II Study of Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed By Consolidation With Cladribine Plus LDAC Alternating With Decitabine in Patients With Untreated Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).
Cladribine; Cytarabine; Decitabine

Acute Myeloid Leukemia (AML), or Myelodysplastic Syndrome (MDS) Clinical Trial using Treosulfan

Center for International Blood and Marrow Transplant Research - Recruiting N/A to 21 years.
- A Phase II Study of Treosulfan/Fludarabine/Low Dose Total Body Irradiation as a Preparative Regimen for Children With AML/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation.
Treosulfan

Acute Myeloid Leukemia (AML), or Myelodysplastic Syndrome (MDS) Clinical Trial

Fred Hutchinson Cancer Research Center - Recruiting 18 years to 80 years.
- Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Chemotherapy for Older and Medically Infirm Patients Diagnosed With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study.

Myelodysplastic Syndrome Clinical Trial using Oral Azacitidine; Placebo

Celgene Corporation - Recruiting 18 years or older.
- A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia Due to IPSS Lower-risk Myelodysplastic Syndromes.
Oral Azacitidine; Placebo

Myelodysplastic Syndromes (MDS), or Acute Myelogenous Leukemia (A Clinical Trial using low dose 5'-azacitidine

Memorial Sloan-Kettering Cancer Center - Recruiting 1 year to 75 years.
- A Single Arm Phase II Trial of Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse.
low dose 5'-azacitidine

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myel Clinical Trial using fludarabine phosphate; cyclophosphamide; total-body irradiation; iodine I 131 monoclonal antibody BC8; allogeneic bone marrow transplantation; tacrolimus; mycophenolate mofetil

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- Hematopoietic Bone Marrow Transplantation for Patients With High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Related HLA-Mismatched Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined With Immunosuppression Before and After Transplantation.
fludarabine phosphate; cyclophosphamide; total-body irradiation; iodine I 131 monoclonal antibody BC8; allogeneic bone marrow transplantation; tacrolimus; mycophenolate mofetil

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using standard follow-up care; medical chart review; quality-of-life assessment

Fred Hutchinson Cancer Research Center - Recruiting 18 years to 75 years.
- Phase 2 Study of Early Discharge and Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML.
standard follow-up care; medical chart review; quality-of-life assessment

Myeldysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia, B Clinical Trial using Clofarabine; Lenalidomide

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Clofarabine Followed by Lenalidomide for Treatment of High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Clofarabine; Lenalidomide

Hematologic Neoplasms, Neural Tube Defects, or Myeloproliferative Clinical Trial using therapeutic allogeneic lymphocytes; Sirolimus

National Institutes of Health Clinical Center (CC) - Recruiting 11 years to 90 years.
- Allogeneic HSCT Without Preparative Chemotherapy or With Low-Intensity Preparative Chemotherapy Using Sirolimus and Sirolimus-Generated Donor Th2 Cells for Therapy of Refractory Leukemia, Lymphoma, Myeloma, or Myelodysplastic Syndrome.
therapeutic allogeneic lymphocytes; Sirolimus

Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Disea Clinical Trial using Cyclophosphamide; rituximab; Methotrexate; Sirolimus; Cyclosporine; Doxorubicin hydrochloride; Etoposide; Fludarabine phosphate; Prednisone; Vincristine sulfate; Cytarabine; Tacrolimus; Alemtuzumab

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 74 years.
- Phase II Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Treatment of Leukemias, Lymphomas, and Pre-malignant Blood Disorders.
Cyclophosphamide; rituximab; Methotrexate; Sirolimus; Cyclosporine; Doxorubicin hydrochloride; Etoposide; Fludarabine phosphate; Prednisone; Vincristine sulfate; Cytarabine; Tacrolimus; Alemtuzumab

MDS Clinical Trial using Darbepoetin alfa; Placebo

Amgen - Recruiting 18 years or older.
- A Multicenter, Randomised, Double-blind, Placebo-controlled Study of Darbepoetin Alfa for the Treatment of Anaemic Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS).
Darbepoetin alfa; Placebo

Myelodysplastic Syndrome Clinical Trial using pracinostat; Placebo; Azacitidine

MEI Pharma, Inc. - Recruiting 18 years or older.
- A Phase 2 Randomized Double-Blind Placebo-Controlled Study of Pracinostat in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate Risk-2 or High-Risk Myelodysplastic Syndrome (MDS).
pracinostat; Placebo; Azacitidine

Myelodysplastic Syndromes, or Thrombocytopenia Clinical Trial using Eltrombopag

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS).
Eltrombopag

Myelodysplastic Syndrome (MDS), Hematologic Neoplasms, Hematologi Clinical Trial using Cord Blood Transplant

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications.
Cord Blood Transplant

Hematologic Disease, Lymphoma, Multiple Myeloma, Myelodysplastic Clinical Trial using Stem cell transplantation

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 80 years.
- Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in High Risk Patients and in Patients With Debilitating Hematologic Diseases.
Stem cell transplantation

Aplastic Anemia, Leukemia, Myelodysplastic Syndrome (MDS), or Lym Clinical Trial using Cord Blood Units

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients.
Cord Blood Units

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adul Clinical Trial using pretargeted radioimmunotherapy; cyclosporine; mycophenolate mofetil; total-body irradiation; nonmyeloablative allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; fludarabine phosphate; pharmacological study

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- Hematopoietic Cell Transplantation for Patients With High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Radiolabeled DOTA-Biotin Pretargeted by BC8 Antibody-Streptavidin Conjugate.
pretargeted radioimmunotherapy; cyclosporine; mycophenolate mofetil; total-body irradiation; nonmyeloablative allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; fludarabine phosphate; pharmacological study

Myelodysplastic Syndrome Clinical Trial using TL32711; 5-Azacitidine

TetraLogic Pharmaceuticals - Recruiting 18 years or older.
- A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Na‹ve, Refractory or Have Relapsed to 5-azacitidine Therapy.
TL32711; 5-Azacitidine

Leukemia Clinical Trial using Quizartinib; Cytarabine; AZA

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Phase I/II Study of the Combination of Quizartinib (AC220) With 5-Azacytidine or Low-Dose Cytarabine for the Treatment of Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Phase I/Phase II.
Quizartinib; Cytarabine; AZA

Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leu Clinical Trial using ex vivo-expanded cord blood progenitor cell infusion; umbilical cord blood transplantation; double-unit umbilical cord blood transplantation; fludarabine phosphate; cyclophosphamide; total-body irradiation; cyclosporine; mycophenolate mofetil; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 6 Months to 45 years.
- Multi-center, Open-label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation With or Without Infusion of Off-The-shelf ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients With Hematologic Malignancies.
ex vivo-expanded cord blood progenitor cell infusion; umbilical cord blood transplantation; double-unit umbilical cord blood transplantation; fludarabine phosphate; cyclophosphamide; total-body irradiation; cyclosporine; mycophenolate mofetil; laboratory biomarker analysis

Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia, Chronic Clinical Trial using clofarabine; cytarabine; busulfan; Plerixafor; cyclophosphamide; antithymocyte globulin (rabbit); stem cells; Tacrolimus; mycophenolate mofetil

St. Jude Children's Research Hospital - Recruiting N/A to 21 years.
- T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant.
clofarabine; cytarabine; busulfan; Plerixafor; cyclophosphamide; antithymocyte globulin (rabbit); stem cells; Tacrolimus; mycophenolate mofetil

Acute Myeloid Leukemia Clinical Trial using PF-04449913; Low dose ARA-C (LDAC); Decitabine; Daunorubicin; Cytarabine; Pf-04449913

Pfizer - Recruiting 18 years or older.
- A Phase 1B/2 Study To Evaluate The Safety And Efficacy Of PF-04449913, An Oral Hedgehog Inhibitor, In Combination With Intensive Chemotherapy, Low Dose Ara-C Or Decitabine In Patients With Acute Myeloid Leukemia Or High Risk Myelodysplastic Syndrome.
PF-04449913; Low dose ARA-C (LDAC); Decitabine; Daunorubicin; Cytarabine; Pf-04449913

Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML); Clinical Trial using CliniMACS CD34+ Reagent System; Thiotepa; Cyclophosphamide; Alemtuzumab; Tacrolimus; Melphalan; Busulfan; Fludarabine

Columbia University - Recruiting N/A to 22 years.
- CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplant for Malignant Disease.
CliniMACS CD34+ Reagent System; Thiotepa; Cyclophosphamide; Alemtuzumab; Tacrolimus; Melphalan; Busulfan; Fludarabine

Adult Patients With Low- and Int-1-risk Myelodysplastic Syndrome Clinical Trial using Erythropoietin alpha; Deferasirox

Novartis - Recruiting 18 years or older.
- An Open-label, Phase II, Randomized, Pilot Study to Assess the Effect in Term of Erythroid Improvement of Deferasirox Combined With Erythropoietin Compared to Erythropoietin Alone in Patients With Low- and Int-1-risk Myelodysplastic Syndrome..
Erythropoietin alpha; Deferasirox

Myelodysplastic Syndrome, or MDS Clinical Trial using pracinostat; Azacitidine; Decitabine

MEI Pharma, Inc. - Recruiting 18 years or older.
- A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone.
pracinostat; Azacitidine; Decitabine

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adul Clinical Trial using iodine I 131 monoclonal antibody BC8; fludarabine phosphate; total-body irradiation; allogeneic hematopoietic stem cell transplantation; cyclosporine; mycophenolate mofetil; peripheral blood stem cell transplantation

Fred Hutchinson Cancer Research Center - Recruiting 16 years to 50 years.
- A Phase II Trial Combining Radiolabeled BC8 (Anti-CD45) Antibody With Fludarabine and Low Dose TBI Followed by Related or Unrelated PBSC Infusion and Post-Transplant Immunosuppression for Patients With Advanced AML or High Risk Myelodysplastic Syndrome.
iodine I 131 monoclonal antibody BC8; fludarabine phosphate; total-body irradiation; allogeneic hematopoietic stem cell transplantation; cyclosporine; mycophenolate mofetil; peripheral blood stem cell transplantation

Myelodysplastic Syndromes Clinical Trial using Lenalidomide

Washington University School of Medicine - Recruiting 18 years or older.
- Phase II Trial of High Dose Lenalidomide in Patients With Myelodysplastic Syndrome Refractory to Hypomethylating Agents.
Lenalidomide

Myelodysplastic Syndrome Clinical Trial

Samsung Medical Center - Recruiting 18 years or older.
- Retrospective Study for Predictive Marker for Decitabine Treament in MDS Patients.

Leukemia, Myelodysplastic Syndrome, or Lymphoma Clinical Trial using CliniMACS Fractionation system (Arm A); CliniMACS Fractionation system (Arm B)

Memorial Sloan-Kettering Cancer Center - Recruiting 2 years to 70 years.
- Myeloablative Unrelated Donor Cord Blood Transplantation With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cells for Patients With High Risk Hematological Malignancies.
CliniMACS Fractionation system (Arm A); CliniMACS Fractionation system (Arm B)

Leukemia, Multiple Myeloma, Myelodysplastic Syndrome, or Non-Hodg Clinical Trial using Palifermin; Lupron; without the addition of palifermin or Lupron; peripheral blood stem cell transplantation

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years to 60 years.
- An Open Label Randomized Phase II Study of Palifermin With or Without Leuprolide Acetate Versus Control for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation.
Palifermin; Lupron; without the addition of palifermin or Lupron; peripheral blood stem cell transplantation

GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia Clinical Trial using milatuzumab

Immunomedics, Inc. - Recruiting 18 years or older.
- A Phase I Study of Milatuzumab (hLL1) for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With Hematologic Malignancies.
milatuzumab

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodyspla Clinical Trial using EPZ-5676

Epizyme, Inc. - Recruiting 18 years or older.
- A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Translocation of the MLL Gene at 11q23 or Advanced Hematologic Malignancies.
EPZ-5676

Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, or Myelod Clinical Trial using Lupron; 18F FLT; Cyclophosphamide; Methotrexate; Tacrolimus; Total Body Irradiation

National Institutes of Health Clinical Center (CC) - Recruiting 8 years to 60 years.
- Multi-Institutional Prospective Pilot Study of Lupron to Enhance Lymphocyte Immune Reconstitution Following Allogeneic Bone Marrow Transplantation in Post-Pubertal Children and Adults With Molecular Imaging Evaluation.
Lupron; 18F FLT; Cyclophosphamide; Methotrexate; Tacrolimus; Total Body Irradiation

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using cytarabine; daunorubicin hydrochloride; etoposide; pomalidomide; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years to 65 years.
- A Phase I Study of Pomalidomide Given at the Time of Lymphocyte Recovery Following Induction Timed Sequential Chemotherapy With Cytarabine, Daunorubicin and Etoposide (AcDVP16) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk MDS.
cytarabine; daunorubicin hydrochloride; etoposide; pomalidomide; laboratory biomarker analysis

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myel Clinical Trial using lenalidomide; laboratory biomarker analysis

Albert Einstein College of Medicine of Yeshiva University - Recruiting 60 years to 75 years.
- A Phase I/II Study of Lenalidomide Maintenance After Autologous Stem Cell Transplant for Elderly Patients With Acute Myeloid Leukemia (AML).
lenalidomide; laboratory biomarker analysis

Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leu Clinical Trial using fludarabine phosphate; cyclosporine; sirolimus; mycophenolate mofetil; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; total-body irradiation

Fred Hutchinson Cancer Research Center - Recruiting N/A or older.
- A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-Center Trial.
fludarabine phosphate; cyclosporine; sirolimus; mycophenolate mofetil; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; total-body irradiation

MDS (Myelodysplastic Syndrome), Myeloproliferative Disorder, Lymp Clinical Trial using Graft Manipulation (CD34+ Selection)

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 80 years.
- Peripheral Blood Stem Cell Allotransplantation For Hematological Malignancies Using Ex Vivo CD34 Selection - a Platform For Adoptive Cellular Therapies.
Graft Manipulation (CD34+ Selection)

Myelodysplastic Syndrome, or Leukemia Clinical Trial using Cord Blood Infusion; Busulfan; Fludarabine; Rituximab; ATG; Cyclophosphamide; Clofarabine; Total Body Irradiation (TBI); Melphalan; Tacrolimus; Mycophenolate Mofetil; G-CSF

M.D. Anderson Cancer Center - Recruiting 1 year to 80 years.
- Cord Blood Expansion on Mesenchymal Stem Cells.
Cord Blood Infusion; Busulfan; Fludarabine; Rituximab; ATG; Cyclophosphamide; Clofarabine; Total Body Irradiation (TBI); Melphalan; Tacrolimus; Mycophenolate Mofetil; G-CSF

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adul Clinical Trial using DEC-205/NY-ESO-1 fusion protein CDX-1401; poly ICLC; decitabine; laboratory biomarker analysis

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Phase I Study of DEC205mAb-NY ESO 1 Fusion Protein (CDX-1401) Given With Adjuvant polyICLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) in Patients With MDS or Low Blast Count AML.
DEC-205/NY-ESO-1 fusion protein CDX-1401; poly ICLC; decitabine; laboratory biomarker analysis

Acute Myeloid Leukemia, Infantile Leukemia (Both AML and ALL), My Clinical Trial using Sorafenib; Cytarabine; Clofarabine

St. Jude Children's Research Hospital - Recruiting N/A to 31 years.
- A Pilot Pharmacokinetic, Pharmacodynamic and Feasibility Study of Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies.
Sorafenib; Cytarabine; Clofarabine

Acute Myeloid Leukemia, or Myelodysplastic Syndromes Clinical Trial using CD8+ T-cell depleted donor lymphocyte infusion

National University Hospital, Singapore - Recruiting 21 years to 90 years.
- Preemptive CD8+ T-cell Depleted Donor Lymphocyte Infusion (DLI) Following Nonmyeloablative Stem Cell Transplantation (NMT) for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS).
CD8+ T-cell depleted donor lymphocyte infusion

Aplastic Anemia, Leukemia, or Myelodysplastic Syndrome Clinical Trial using Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine.; CliniMACS device

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- A Multicenter Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine.
Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine.; CliniMACS device

Multiple Myeloma, Myelodysplastic Syndrome, Hodgkin's Lymphoma, o Clinical Trial using MK-3475

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase Ib Multi-Cohort Trial of MK-3475 in Subjects With Hematologic Malignancies.
MK-3475

Leukemia, or Myelodysplastic Syndrome Clinical Trial using ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- Phase I Trial of Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies.
ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195

Myelodysplastic Syndrome, or Acute Myeloid Leukemia Clinical Trial using BX2; BX3; BX4

Institut Paoli-Calmettes - Recruiting 18 years to 65 years.
- Prospective and Multicentre Evaluation of 3 Different Doses of IV Busulfan Associated With Fludarabine and Thymoglobuline in the Conditioning of Allogeneic Stem Cell Transplantation (SCT) From a Matched Related or Unrelated Donor in Patients With Poor Prognosis Myeloid Malignancies.
BX2; BX3; BX4

Myelodysplastic Syndrome, MDS, or Trisomy 8 Clinical Trial using rigosertib

Onconova Therapeutics, Inc. - Recruiting 18 years or older.
- A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification.
rigosertib

Myelodysplastic Syndrome Clinical Trial using SyB C-1101

SymBio Pharmaceuticals - Recruiting 20 years or older.
- Phase I Clinical Trial of SyB C-1101 in Patients With Myelodysplastic Syndrome.
SyB C-1101

Myelodysplastic Syndromes Clinical Trial using vosaroxin; Azacitidine

Washington University School of Medicine - Recruiting 18 years or older.
- A Phase I Study of Vosaroxin Plus Azacitidine for Patients With Myelodysplastic Syndrome.
vosaroxin; Azacitidine

Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leu Clinical Trial using temozolomide; veliparib; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Study of the PARP Inhibitor ABT-888 in Combination With Temozolomide in Acute Leukemias.
temozolomide; veliparib; pharmacological study; laboratory biomarker analysis

For Donors:, Related Donors Donating PBSC to a Family Member, For Clinical Trial using Plerixafor

Center for International Blood and Marrow Transplant Research - Recruiting 18 years to 65 years.
- A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies.
Plerixafor

Acute Lymphoblastic Leukemia, Non Hodgkins Lymphoma, Myelodysplas Clinical Trial using Ara-C; Cyclophosphamide; Campath-1H; Total Body Irradiation; Stem Cell Infusion

Baylor College of Medicine - Recruiting N/A to 55 years.
- CD-34 Selection for Ex-vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts Receiving Intensive Conditioning.
Ara-C; Cyclophosphamide; Campath-1H; Total Body Irradiation; Stem Cell Infusion

Myelodysplastic Syndrome (MDS), or Severe Aplastic Anemia (SAA) Clinical Trial using Umbilical Cord Blood; Haploidentical Stem Cells; Miltenvi CliniMACs CD34 Reagent System

National Institutes of Health Clinical Center (CC) - Recruiting 4 years to 75 years.
- Co-Infusion of Umbilical Cord Blood and Haploidentical CD34+ Cells Following Nonmyeloablative Conditioning as Treatment for Severe Aplastic Anemia and MDS Associated With Severe Neutropenia Refractory to Immunosuppressive Therapy.
Umbilical Cord Blood; Haploidentical Stem Cells; Miltenvi CliniMACs CD34 Reagent System

GVHD, Adult Acute Myeloid Leukemia, Adult Acute Lymphoid Leukemia Clinical Trial using US-ATG-F; Placebo

Neovii Biotech - Recruiting 18 years to 65 years.
- Phase 3 Study of US-ATG-F to Prevent Moderate to Severe Chronic GVHD in Adult Acute Myeloid Leukemia, Acute Lymphoid Leukemia, and Myelodysplastic Syndrome Patients After Allogeneic Stem Cell Transplantation From Unrelated Donors.
US-ATG-F; Placebo

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myel Clinical Trial using WT1-sensitized T cells; aldesleukin; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting N/A or older.
- Phase I/II Study of Adoptive Immunotherapy After Allogeneic HCT With Virus Specific CD8+ T Cells That Have Been Transduced to Express a WT1-specific T Cell Receptor for Patients With High Risk or Relapsed AML, MDS, or CML.
WT1-sensitized T cells; aldesleukin; laboratory biomarker analysis

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using chemotherapy

University of Washington - Recruiting 18 years to 59 years.
- Feasibility of Outpatient Induction Chemotherapy for Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome.
chemotherapy

Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Chronic My Clinical Trial using HSC835

Novartis - Recruiting 10 years to 55 years.
- A First-in-human, Single-arm, Single-center, Open-label, Proof-of-concept Study to Evaluate the Safety and Tolerability of Infusing HSC835 (LFU835-expanded Umbilical Cord Blood Hematopoietic Stem Cells) in Patients With Hematological Malignancies.
HSC835

Leukemia, Myeloid, Chronic, Lymphomas, Multiple Myeloma, Myelodys Clinical Trial using Donor Lymphocyte Infusion; Induction Chemotherapy + DLI

Masonic Cancer Center, University of Minnesota - Recruiting 1 year to 70 years.
- Use of Cyclophosphamide/Fludarabine to Promote in Vivo Expansion of Donor Lymphocyte Infusions (DLI) to Enhance Efficacy After Allogeneic Transplant.
Donor Lymphocyte Infusion; Induction Chemotherapy + DLI

Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL), A Clinical Trial using NiCordr

Gamida Cell ltd - Recruiting 18 years to 65 years.
- Allogeneic Stem Cell Transplantation of NiCordr, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adult Patients With Hematological Malignancies.
NiCordr

Myelodysplastic Syndrome Clinical Trial using Decitabine; Clofarabine

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Randomized Study of Decitabine Alternating With Clofarabine Versus Decitabine Until Failure in Patients With Higher Risk Myelodysplastic Syndromes (MDS).
Decitabine; Clofarabine

Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Lymphoma Clinical Trial using Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG); Stem Cell Transplant; Stem Cells Collections; Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI); Fludarabine, Busulfan, and ATG

University of Chicago - Recruiting 1 year or older.
- Combined Haploidentical-Cord Blood Transplantation for Adults and Children.
Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG); Stem Cell Transplant; Stem Cells Collections; Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI); Fludarabine, Busulfan, and ATG

Previously Treated Myelodysplastic Syndromes Clinical Trial using 6,8-bis(benzylthio)octanoic acid

Comprehensive Cancer Center of Wake Forest University - Recruiting 18 years or older.
- A Pilot Study of CPI-613 in Patients With Myelodysplastic Syndrome Who Have Failed Previous Therapy.
6,8-bis(benzylthio)octanoic acid

Leukemia, Myeloid, Acute, or Myelodysplastic Syndromes Clinical Trial using Azacitidine; Pre-DLI Salvage Chemotherapy; Donor Leukocyte Infusion (DLI)

Washington University School of Medicine - Recruiting 18 years or older.
- A Phase I Study of the Safety and Feasibility of Azacitidine After Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome After Allogeneic Stem Cell Transplantation.
Azacitidine; Pre-DLI Salvage Chemotherapy; Donor Leukocyte Infusion (DLI)

Myelodysplastic Syndrome, MDS, or Anemia Clinical Trial using Lenalidomide; Eltrombopag

Albert Einstein College of Medicine of Yeshiva University - Recruiting 18 years or older.
- PHASE II STUDY OF LENALIDOMIDE AND ELTROMBOPAG IN PATIENTS WITH SYMPTOMATIC ANEMIA IN LOW OR INTERMEDIATE I MYELODYSPLASTIC SYNDROME (MDS).
Lenalidomide; Eltrombopag

Acute Myelogenous Leukemia, Acute Lymphoid Leukemia, Myeloprolife Clinical Trial using ARM A Cyclophosphamide; ARM B Calcineurin inhibitor and methotrexate

Hospital Israelita Albert Einstein - Recruiting 18 years to 60 years.
- Randomized Study to Compare Post Bone Marrow Transplant Cyclophosphamide With the Combination of Methotrexate Plus Calcineurin Inhibitor for Graft Versus Host Disease Prophylaxis.
ARM A Cyclophosphamide; ARM B Calcineurin inhibitor and methotrexate

Myelodysplastic Syndrome Clinical Trial using Azacitidine

Seoul St. Mary's Hospital - Recruiting 18 years to 80 years.
- A Randomized, Phase II, Comparative Study With a Parallel Control for Evaluating the Efficacy and Safety of 5-day Azacitidine for Patients With Lower-risk Myelodysplastic Syndrome.
Azacitidine

Acute Leukemia, Chronic Leukemia, Myelodysplastic Syndrome, Lymph Clinical Trial using Ex vivo expanded cord blood cells

Singapore General Hospital - Recruiting 12 years to 60 years.
- Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells: A Pilot Trial in Collaboration With the Massachusetts Institute of Technology.
Ex vivo expanded cord blood cells

Acute Leukemia, Myelodysplastic Syndrome, or Solid Tumors Clinical Trial using anti-thymocyte globulin; filgrastim; Total body irradiation; Fludarabine; cyclophosphamide; Tacrolimus; Mycophenolate mofetil; Rituximab

Asan Medical Center - Recruiting N/A to 21 years.
- HLA-haploidentical Allogeneic Hematopoietic Cell Transplantation Using CD3 Depletion for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors After Conditioning of TBI, Fludarabine, Cyclophosphamide and Antithymocyte Globulin.
anti-thymocyte globulin; filgrastim; Total body irradiation; Fludarabine; cyclophosphamide; Tacrolimus; Mycophenolate mofetil; Rituximab

Dyskeratosis Congenita, Fanconi Anemia, Myelodysplastic Syndromes Clinical Trial using polymerase chain reaction; flow cytometry; immunologic technique; biopsy

University Hospital Freiburg - Recruiting N/A to 17 years.
- TCR Vbeta Repertoire and PNH Clones in Children With Refractory Cytopenia (RC). An Open Nonrandomised Multi-Center Prospective Study.
polymerase chain reaction; flow cytometry; immunologic technique; biopsy

Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia Clinical Trial using allogeneic stem cell transplantation; 5-azacytidine until progress

Universit„tsklinikum Hamburg-Eppendorf - Recruiting 55 years to 70 years.
- Comparison Between 5-azacytidine Treatment and 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability.
allogeneic stem cell transplantation; 5-azacytidine until progress

Multiple Myeloma, Lymphoma, Acute Myelogenous Leukemia, Acute Lym Clinical Trial using Tacrolimus and MMF

Colorado Blood Cancer Institute - Recruiting 50 years to 70 years.
- Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression After Conditioning With Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA-Matched Family Donor Hematopoietic Cell Transplants.
Tacrolimus and MMF